No. 23andMe is considered a direct-to-consumer genetic testing company, and transactions with the company are considered commercial, not medical. Because 23andMe is not a medical company, customers' ...
Shares were hovering below $1 until 23andMe announced a 1-for-20 reverse stock split in October. In September, all seven of ...
DNA-testing company 23andMe said on Monday that it was firing roughly ... The company announced two weeks ago that it had ...
On Tuesday, Wojcicki announced the new additions to 23andMe’s board: Andre Fernandez, a former CFO at WeWork, Inc., and NCR ...
Back in September, all of 23andMe’s independent directors also resigned from its board — in a rare move that followed ...
The company said Tuesday it has appointed Andre Fernandez, Jim Frankola and Mark Jensen as independent board members. The trio will serve on 23andMe's audit committee and compensation committee.
In September, independent directors of the Board of 23andMe sent a letter to Anne Wojcicki, Chief Executive Officer, Co ...
Embattled genetic testing provider 23andMe said on Tuesday that revenue declined from a year earlier, a day after the company ...
In another blow to the company, seven of 23andMe’s eight-strong board resigned in September. The firm's independent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback